Pakeeza Sayyed

689 total citations
16 papers, 561 citations indexed

About

Pakeeza Sayyed is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Pakeeza Sayyed has authored 16 papers receiving a total of 561 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 7 papers in Pathology and Forensic Medicine and 7 papers in Oncology. Recurrent topics in Pakeeza Sayyed's work include Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (7 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Pakeeza Sayyed is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (7 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Pakeeza Sayyed collaborates with scholars based in Switzerland, United Kingdom and France. Pakeeza Sayyed's co-authors include Saghir Akhtar, Marcus D. Hughes, M. Bibby, John A. Double, Christine McIntyre, Stephen Fox, Ibrahim F. Benter, Gordon Beck, Keng Wooi Ng and Mustapha Benboubetra and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Pakeeza Sayyed

16 papers receiving 535 citations

Peers

Countries citing papers authored by Pakeeza Sayyed

Since Specialization

Citations

This map shows the geographic impact of Pakeeza Sayyed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pakeeza Sayyed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pakeeza Sayyed more than expected).

Fields of papers citing papers by Pakeeza Sayyed

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pakeeza Sayyed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pakeeza Sayyed. The network helps show where Pakeeza Sayyed may publish in the future.

Co-authorship network of co-authors of Pakeeza Sayyed

This figure shows the co-authorship network connecting the top 25 collaborators of Pakeeza Sayyed. A scholar is included among the top collaborators of Pakeeza Sayyed based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pakeeza Sayyed. Pakeeza Sayyed is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	1382P Phase Ib/II open-label, randomised evaluation of second-line atezolizumab (atezo) + linagliptin (lina) vs ramucirumab (ram) + paclitaxel (pac) in MORPHEUS-gastric cancer 2021 ·Annals of Oncology ·(unknown), Jaffer A. Ajani, (unknown), Y-K. Kang, (unknown), Simon Allen, N. Al-Sakaff, Jérémie Decalf, (unknown), (unknown), Pakeeza Sayyed, Y-J. Bang	1
2	Phase Ib/II open-label, randomized evaluation of efficacy and safety of atezolizumab plus isatuximab versus regorafenib in MORPHEUS-colorectal cancer. 2021 ·Journal of Clinical Oncology ·Jayesh Desai, Marwan Fakih, Katrina S. Pedersen, Yong Sang Hong, Neil H. Segal, Simon Allen, (unknown), (unknown), (unknown), Pakeeza Sayyed, (unknown), Michael Cecchini	3
3	1315P Phase Ib/II open-label, randomised evaluation of atezolizumab (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer) 2020 ·Annals of Oncology ·Enriqueta Felip, (unknown), Melissa L. Johnson, Mary O’Brien, Fabrice Barlési, Julien Mazières, Benjamin Solomon, Víctor Moreno, Valentina Boni, Aurélie Swalduz, Sarah B. Goldberg, Bhumsuk Keam, Steven G. Allen, (unknown), Colby S. Shemesh, (unknown), N. Al-Sakaff, (unknown), Pakeeza Sayyed, Byoung Chul Cho	6
4	Abstract CT201: Phase Ib/II open-label, randomized evaluation of atezolizumab + cobimetinib vs control in MORPHEUS-NSCLC (non-small cell lung cancer), MORPHEUS-PDAC (pancreatic ductal adenocarcinoma) and MORPHEUS-GC (gastric cancer) 2020 ·Cancer Research ·Byoung Chul Cho, Nathan Bahary, Johanna C. Bendell, Enriqueta Felip, Melissa L. Johnson, Yoon‐Koo Kang, Farah Louise Lim, Teresa Macarulla, Gulam A. Manji, Do‐Youn Oh, Osama E. Rahma, Simon Allen, Edward Cha, (unknown), Hans‐Joachim Helms, (unknown), Pakeeza Sayyed, (unknown), Kyu‐pyo Kim	3
5	MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types 2018 ·Annals of Oncology ·Ian Chau, Georg Martin Haag, Osama E. Rahma, Teresa Macarulla, Steve McCune, Denise A. Yardley, Benjamin Solomon, Melissa L. Johnson, Gregory A. Vidal, Peter Schmid, Guillem Argilés, (unknown), Sami Mahrus, Noor Hisham Abdullah, (unknown), Pakeeza Sayyed, Hila Barak, Conrad C. Bleul, Edward Cha, Alexandra Drakaki	14
6	MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer. 2018 ·Journal of Clinical Oncology ·Do‐Youn Oh, Salah‐Eddin Al‐Batran, Hyun Cheol Chung, Antoine Hollebecque, Syma Iqbal, Kyu‐pyo Kim, Jill Lacy, Gulam A. Manji, Eileen M. O’Reilly, Osama E. Rahma, Harry H. Yoon, Antonia Kwan, Xian He, Hila Barak, Pakeeza Sayyed, Xiaosong Zhang, Jun Wang, Edward Cha, Tanios Bekaii‐Saab	7
7	Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial 2016 ·The Lancet Haematology ·Sarit Assouline, Valéria Buccheri, Alain Delmer, Gianluca Gaïdano, Marek Trněný, (unknown), Michael Brewster, Olivier Catalani, Sai Li, Christine McIntyre, Pakeeza Sayyed, Xavier C. Badoux	35
8	Practical experience with rituximab subcutaneous 2015 ·Cancer Nursing Practice ·Sarah Liptrott, (unknown), (unknown), (unknown), (unknown), Pakeeza Sayyed	1
9	Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia 2015 ·British Journal of Clinical Pharmacology ·Sarit Assouline, Valéria Buccheri, Alain Delmer, Gianluca Gaïdano, Christine McIntyre, Michael Brewster, Olivier Catalani, Florence Hourcade‐Potelleret, Pakeeza Sayyed, Xavier C. Badoux	31
10	Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study 2014 ·Journal of Clinical Oncology ·Antonio Salar, Irit Avivi, Beate Bittner, Réda Bouabdallah, Mike Brewster, Olivier Catalani, George Follows, Andrew Haynes, Florence Hourcade‐Potelleret, Andrea Janíková, Jean-François Larouche, Christine McIntyre, (unknown), Juliana Pereira, Pakeeza Sayyed, Ofer Shpilberg, Gayane Tumyan	75
11	Final Results of the BP22333 Study Demonstrate Non-Inferior Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Administration of Rituximab Compared with Intravenous (IV) Administration As Maintenance Therapy in Patients with Follicular Lymphoma (FL) 2012 ·Blood ·Antonio Salar, Irit Avivi, Jean-François Larouche, Andrea Janíková, Juliana Pereira, Mike Brewster, Olivier Catalani, Christine McIntyre, Pakeeza Sayyed, Andrew Haynes	7
12	Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab 2012 ·Blood ·Sarit Assouline, Valéria Buccheri, Alain Delmer, Gottfried Doelken, Gianluca Gaïdano, Christine McIntyre, Mike Brewster, Florence Hourcade‐Potelleret, Pakeeza Sayyed, Xavier C. Badoux	5
13	A Two-Stage Phase Ib Study to Investigate the Pharmacokinetics, Safety and Tolerability of Subcutaneous Rituximab In Patients with Follicular Lymphoma as Part of Maintenance Treatment 2010 ·Blood ·Antonio Salar, Réda Bouabdallah, Christine McIntyre, Pakeeza Sayyed, Beate Bittner	9
14	Sustained Polymeric Delivery of Gene Silencing Antisense ODNs, siRNA, DNAzymes and Ribozymes:In VitroandIn VivoStudies 2004 ·Journal of drug targeting ·(unknown), Mustapha Benboubetra, Pakeeza Sayyed, Keng Wooi Ng, Stephen Fox, Gordon Beck, Ibrahim F. Benter, Saghir Akhtar	107
15	The cellular delivery of antisense oligonucleotides and ribozymes 2001 ·Drug Discovery Today ·Marcus D. Hughes, (unknown), (unknown), Pakeeza Sayyed, Saghir Akhtar	84
16	The delivery of antisense therapeutics 2000 ·Advanced Drug Delivery Reviews ·Saghir Akhtar, Marcus D. Hughes, (unknown), M. Bibby, (unknown), (unknown), John A. Double, Pakeeza Sayyed	173

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact